The Turkish pharma market having an end-user spend of US $9.1 billion, is already the sixth largest in Europe, with around 80 production facilities, 20,000 employees and direct access to the pharma markets of the Middle East and North Africa. Pharmaceutical sales in Turkey have quadrupled over the last decade and it is one of the fastest-growing pharmaceutical markets in the world.
Turkey, which is already established as the regional pharmaceutical hub, and with the fastest growth rate in the OECD – averaging 6.7 per cent per year from 2011-2018, is working towards the Government’s target of becoming a top 10 global healthcare economy by 2023.
In the last few years, there has been a surge of industrialisation within Turkey, as the population gentrifies, and as a result, demand for higher quality pharmaceutical products is increasing. In fact, the Turkish Ministry of Science, Industry, and Technology (AIFD)’s Strategy Report, confidently predicts that the country is set to become the regional production base for medium- and high-level technology products.
Another factor contributing to rising international interest is that the Turkish pharma market still relies heavily on imports, representing 50 per cent of the total industry output. However, a critical consideration for international suppliers looking at market entry is access to robust business intelligence to inform better decisions.
Growing role of CPhI Istanbul
CPhI Istanbul has cemented its role as the key event for pharmaceutical solution suppliers from across Turkey, the Balkans, the Middle East and North Africa, and South East Europe, generating further opportunities for growth and boosting the Turkish and surrounding economies.
The event will provide exhibitors with access to domestic and international attendees looking for innovation and solutions across pharma ingredients, machinery, contract services and pharma packaging, and deliver pharmaceutical products across Eurasia.
The Eurasian pharma and healthcare market is divided among different economies with growing health services. Each for this is generating it own reimbursement programmes, and as there is more government spend and focus on the pharma industries, there is also greater access to new and innovative products and generic formulations.
CPhI Istanbul 2016
CPhI Istanbul 2016, organised by UBM EMEA, returns for the third consecutive year to Turkey, co-located with InnoPack, ICSE and P-MEC. The four-in-one event will take place at the Istanbul Congress Center (ICC), Turkey, from June 1 to 3, 2016, and is heavily supported by the Ministry of Health (Turkish Medicines and Medical Devices Agency) and the Pharmaceutical Manufacturers Association of Turkey (IEIS) – highlighting the integral role it is playing in stimulating regional growth.
Together, these four-events-in-one, provide domestic and international visitors with unrivalled access to global suppliers of raw materials, machinery, pharma packaging solutions and contract services
CPhI Istanbul will be running a high level conference in parallel to the exhibition – specifically designed to provide vital market information, key growth opportunities, and create new strategic alliances to ensure future business success.
According to Haluk Balci, COO , UBM Turkey, over 4,200 visitors from around the world will attend the event over three days, looking to take full advantage of the meeting point CPhI provides to connect with industry executives and develop business opportunities.
This year, CPhI Istanbul will welcome more than 200 exhibitors from more than 20 countries, a similar number to 2015. There are also 30 exhibitors from India as well as regional heavyweights such as DEVA, Nobel Ilac, and Pharmactive.
This event has already been a huge success in the last three years and continues to showcase both the international and domestic appetite for pharmaceutical business. With many international attendees, and the support of regional industry and government, this event is now integral to the progressive advancement of manufacturing. It’s a diverse and evolving market, so to maximise the opportunities available, CPhI also provides a huge content platform to help both attendees and exhibitors make better-informed decisions and see the full scope of potential in this high-growth region.
Other highlights at CphI Istanbul 2016 include:
Matchmaking Programme: For the first time, CPhI’s eponymous Matchmaking Programme comes to Istanbul, complimentary to all attendees . This programme provides the opportunity to actively target the companies that best match individual business needs. It includes a dedicated area solely designated to hosting meetings and allows attendees to pre-plan their schedules and make the most productive use of business opportunities.
Round Table Sessions will be held, with representatives including analysts, consultants, regulatory bodies, academics and pharmaceutical manufacturing companies. Each 30-minute session will focus on the full spectrum of business critical and pharma market issues, with a maximum of 10 attendees at a time.
C-Summit, supported by Fortune Turkey Magazine, gathers the leading CEO’s in the Pharma industry to discuss key issues in the market. This high level summit will take place on the show floor, with discussions centred on how to establish long-term partnerships in Eurasia, market advantages and limitations, as well as the road map for next five years in the region.
Women’s Networking Breakfast will feature a panel discussion on “Breaking the Glass Ceiling” and is designed to support networking and further empower female executives as business leaders in pharma.
CPhI Istanbul Conference
Besides the exhibition, an integrated conference platform will provide insights on key legislative and regulatory updates, sound advisory intelligence and independent practical insights. CPhI Istanbul Conference is a timely event, specifically designed to fill the knowledge and networking needs of industry executives who are in charge of manufacturing, as well as key decision makers responsible for strategic moves regarding capacity planning, business development and technology investment.
“This year the agenda has been formulated through a unique framework that draws from multiple sources of real-world feedback, including; attendee surveys, end-user focus groups, front-line discussions with industry executives and clients, and research metrics, which resulted in a highly relevant, action-oriented agenda with a fresh perspective on regional pharma industry from a scientific, regulatory and technology standpoint, as well as insights from a variety of stakeholders and new thinking about how to resolve challenges and maximise opportunities,” says Balci.
The event will create a unique opportunity to hear from many experienced speakers, all experts in their fields, analysing and uncovering key success factors on design, operation and strategic decision making.
“There will over 300 speakers and delegates with their backgrounds of solution providers, science and technology experts, consultants, government representatives and the pharma community will come together, address main industry issues, reaffirm and optimise existing relationships and create new strategic alliances to ensure future business success”, Balci adds.
The free-to-attend conference is focused on key legislative and regulatory updates, providing sound advisory intelligence and independent practical insights for pharma manufacturers, and domestic/international buyers and suppliers. The programme is built around six core areas: ‘Policy & Regulation’, ‘Business & Investment’, ‘Manufacturing’, ‘R&D, Innovation & New Technologies’, ‘Supply Chain’ and ‘Foreign Markets’.
The conference bridges both East and West perspectives, and key sessions include: ‘Positioning Turkey as a Regional Pharmaceutical Hub’; ‘Creating an R&D Centre Based on Entrepreneurship & Innovation: The Case for Turkey as a Pharmerging Country’; ‘Generating Value through Innovation: What the Turkish Pharma Industry Has to Offer within MENA Context?’; and ‘The Case for Turkey: Transition from Import to Local Production in Pharmaceuticals and Subsequent Need for Harmonising Supply Chain Structures’.
The event will also provide the platform to bring several perspectives together from both Asia and Europe, through its key sessions which will be addressing a wide range of topics. Topics ranging right from innovation, R&D to supply chains and developing pharma industry of the whole region will be covered.
CPhI Istanbul is also a part of the Hosted Buyers Programme from the Turkish Ministry of Economy, which allows for the costs of eligible buyers to be covered by the Turkish Government.
Focus on legislative and regulatory updates
This year’s enlarged agenda will focus on key legislative and regulatory updates and will provide sound advisory intelligence and independent practical insight for pharma manufacturers, domestic and international buyers and suppliers, thinkers and creators that are breaking new ground in formulation, process development, packaging, technology, and more.
Exhibitor seminars will have exhibiting companies present forward thinking perspectives on their key products, innovations, services to the visitors and the press on the show floor.
The 2015 edition of CPhI Istanbul attracted over 4,000 attendees, both local and international. The event focus covered opportunities for generics, super-generics and establishing Turkey as the manufacturing hub of the region. The conference also included updates on the Middle East & North Africa market and the Russia, CIS and emerging markets.